Featured Publications
Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations
Morse E, Judson B, Husain Z, Burtness B, Yarbrough WG, Sasaki C, Cheraghlou S, Mehra S. Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations. Otolaryngology 2018, 159: 987-997. PMID: 30060700, DOI: 10.1177/0194599818779052.Peer-Reviewed Original ResearchHPV-positive patientsRadiation treatment durationTotal treatment packageOverall survivalTreatment initiationTreatment durationEnd intervalOropharyngeal cancerTreatment delayTreatment packageOropharyngeal squamous cell carcinomaCox proportional hazards regressionMultivariable logistic regression analysisRadiation treatmentRetrospective cross-sectional analysisNational Cancer DatabaseProportional hazards regressionSquamous cell carcinomaDuration of diagnosisLogistic regression analysisNational benchmarksCross-sectional analysisMedian durationOverall cohortHazards regression
2023
Role of PET/CT in Oropharyngeal Cancers
Avery E, Joshi K, Mehra S, Mahajan A. Role of PET/CT in Oropharyngeal Cancers. Cancers 2023, 15: 2651. PMID: 37174116, PMCID: PMC10177278, DOI: 10.3390/cancers15092651.Peer-Reviewed Original Research
2021
A 2020 Update on Public Awareness of Head and Neck Cancers
Torabi SJ, Kasle DA, Su-Velez B, Mehra S, Day TA, Yarbrough WG, St. John M, Judson BL. A 2020 Update on Public Awareness of Head and Neck Cancers. Otolaryngology 2021, 166: 305-312. PMID: 33845657, DOI: 10.1177/01945998211006932.Peer-Reviewed Original ResearchConceptsHuman papillomavirusHPV's roleNeck cancerNeck Cancer Awareness WeekKnowledge of HNCSigns/symptomsFormer tobacco usersCross-sectional surveyFormer smokersOropharyngeal cancerRisk factorsTobacco usersElderly individualsRisk populationsAwareness rateUS populationOlder individualsFuture outreach effortsCancerCausal roleHNCAwareness WeekUS CensusExposureHead
2020
Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer
Jacobs D, Torabi SJ, Park HS, Rahmati R, Young MR, Mehra S, Judson BL. Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer. Otolaryngology 2020, 164: 1240-1248. PMID: 33198564, DOI: 10.1177/0194599820969613.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseHPV-negative oropharyngeal cancersChemoradiation therapyOverall survivalCancer DatabaseOropharyngeal cancerHPV-negative oropharyngeal squamous cell carcinomaLarge national cancer databaseNeck cancer-specific survivalOropharyngeal squamous cell carcinomaCox proportional hazards regressionKaplan-Meier survival analysisCancer-specific survivalImproved overall survivalMultivariable Cox regressionRetrospective cohort studyAdjuvant chemoradiation therapyUse of surgeryEnd Results ProgramProportional hazards regressionSquamous cell carcinomaSEER cohortAdjuvant therapyCohort studySEER database
2019
OA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition
Miccio J, Kelly J, Kann B, An Y, Park H, Verma V, Mehra S, Judson B, Burtness B, Husain Z. OA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e1. DOI: 10.1016/s0360-3016(19)30402-x.Peer-Reviewed Original Research
2018
National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation
Morse E, Judson B, Husain Z, Burtness B, Yarbrough W, Sasaki C, Cheraghlou S, Mehra S. National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation. Oral Oncology 2018, 82: 122-130. PMID: 29909886, DOI: 10.1016/j.oraloncology.2018.02.010.Peer-Reviewed Original ResearchConceptsRadiation treatment durationHuman papilloma virus-positive tumorsVirus-positive tumorsOverall survivalOropharyngeal cancerTreatment durationTreatment endMedian durationTreatment initiationTreatment delayHuman papilloma virus-associated tumorsHuman papilloma virus-negative tumorsEnd intervalOropharyngeal squamous cell carcinomaCox proportional hazards regressionNational Cancer DatabaseProportional hazards regressionSquamous cell carcinomaVirus-associated tumorsVirus-negative tumorsMultivariable logisticHazards regressionCell carcinomaHuman papillomaCancer Database
2017
Treatment deintensification in human papillomavirus‐positive oropharynx cancer: Outcomes from the National Cancer Data Base
Cheraghlou S, Yu PK, Otremba MD, Park HS, Bhatia A, Zogg CK, Mehra S, Yarbrough WG, Judson BL. Treatment deintensification in human papillomavirus‐positive oropharynx cancer: Outcomes from the National Cancer Data Base. Cancer 2017, 124: 717-726. PMID: 29243245, DOI: 10.1002/cncr.31104.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseStage III diseaseTriple-modality therapyAdjuvant radiotherapyOropharyngeal cancerStage IHuman papillomavirus-positive oropharyngeal cancerUnivariate Kaplan-Meier analysisAvoidance of chemotherapyDeintensification of treatmentEdition stage IStage II diseaseMultivariate Cox regressionAmerican Joint CommitteeKaplan-Meier analysisDisease stage groupsForm of treatmentTreatment deintensificationAdjuvant chemoradiotherapyDefinitive radiotherapyTreatment intensificationFavorable prognosisImproved survivalCox regressionRetrospective study